Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals
暂无分享,去创建一个
K. Seung | D. Waters | J. Jukema | R. McPherson | J. Ferrières | R. Santos | C. Brotons | J. Foody | L. Tarasenko | Michael Messig | C. Chiang | J. Verdejo | D. Waters
[1] A. Gotto,et al. Improving lipid goal attainment: is it enough? , 2009, Circulation.
[2] S. King,et al. Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required , 2008, Circulation.
[3] M. Sabatine,et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. , 2008, Journal of the American College of Cardiology.
[4] Marc A Pfeffer,et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. , 2008, Journal of the American College of Cardiology.
[5] J. Bernarding,et al. Achievement of guideline-defined treatment goals in primary care: the German Coronary Risk Management (CoRiMa) study. , 2007, European heart journal.
[6] R. Karas,et al. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. , 2007, The American journal of cardiology.
[7] R. Gangnon,et al. Implications of Cardiac Risk and Low-Density Lipoprotein Cholesterol Distributions in the United States for the Diagnosis and Treatment of Dyslipidemia: Data From National Health and Nutrition Examination Survey 1999 to 2002 , 2007, Circulation.
[8] Lawrence A Leiter,et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. , 2006, The American journal of medicine.
[9] Christopher P Cannon,et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.
[10] A. González-Quintela,et al. [Prevalence of cardiovascular risk factors in the Spanish working population]. , 2006, Revista espanola de cardiologia.
[11] E. D. de Faria,et al. The use of a hospital laboratory cohort to estimate the prevalence of dyslipidemia in an adult Brazilian population. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[12] M. A. Sánchez-Chaparro,et al. Prevalencia de factores de riesgo vascular en la población laboral española , 2006 .
[13] E. Bruckert,et al. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients , 2005, Current medical research and opinion.
[14] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[15] J. Mckenney,et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. , 2005, The American journal of cardiology.
[16] D. Arveiler,et al. [Prevalence of dyslipidaemias in a representative sample of the French population]. , 2005, Archives des maladies du coeur et des vaisseaux.
[17] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[18] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2004, European heart journal.
[19] R. McPherson,et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[20] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .
[21] J. Mckenney,et al. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .
[22] S. Heymsfield,et al. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. , 2002, The American journal of clinical nutrition.
[23] T. Pearson,et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.
[24] J. Little,et al. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group. , 1999, The Canadian journal of cardiology.
[25] David M. Herrington,et al. Adherence to National Cholesterol Education Program Treatment Goals in Postmenopausal Women With Heart Disease: The Heart and Estrogen/Progestin Replacement Study (HERS) , 1997 .
[26] Bittner,et al. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. , 1997, JAMA.
[27] T. Wilt,et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. , 1995, The American journal of cardiology.
[28] G. Dagenais,et al. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study) , 1995, The American journal of cardiology.
[29] G. Moneta. Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals , 2010 .
[30] Michael Miller. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[31] S. Grundy,et al. National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .
[32] David R. Wood,et al. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.
[33] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .